RT Journal Article
SR Electronic
T1 A quantum-enhanced precision medicine application to support data-driven clinical decisions for the personalized treatment of advanced knee osteoarthritis: development and preliminary validation of precisionKNEE_QNN
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267704
DO 10.1101/2021.12.13.21267704
A1 Nima Heidari
A1 Stefano Olgiati
A1 Davide Meloni
A1 Federico Pirovano
A1 Ali Noorani
A1 Mark Slevin
A1 Leonard Azamfirei
YR 2022
UL http://medrxiv.org/content/early/2022/03/07/2021.12.13.21267704.abstract
AB Background The clinical problem of knee osteoarthritis is that, although some novel therapies are safe and effective, the response is variable, and defining the features that predict individual response remains a challenge. Variational quantum-classical and quantum machine learning (QML) algorithms based on parameterized quantum circuits (PQC) are promising experimental technologies which can improve the efficiency of precision medicine clinical decision support systems (CDSS) based on real-world data stored in large unstructured databases. In this paper we tested a quantum neural network (QNN) application to support precision data-driven clinical decisions to select personalized treatments for advanced knee osteoarthritis.Methods Following patients’ consent and Research Ethics Committee approval, we collected clinico-demographic data before and after the treatment from 170 patients eligible for knee arthroplasty (Kellgren-Lawrence grade ≥ 3, OKS ≤ 27, Age ≥ 64 and idiopathic aetiology of arthritis) treated over a 2 year period with a single injection of microfragmented fat. Gender classes were balanced (76 M, 94 F) to mitigate gender bias. A patient with an improvement ≥ 7 OKS has been considered a Responder. We trained our QNN Classifier on a randomly selected training subset of 113 patients to classify responders from non-responders (73 R, 40 NR) in pain and function at 1 year. Outliers were hidden from the training dataset but not from the validation set. We ran our QNN Classifier on a IBM quantum simulator to reduce the error due to noise.Results We tested our QNN Classifier on a randomly selected test subset of 57 patients (34 R, 23 NR) including outliers. The No Information Rate was equal to 0.59. Our application correctly classified 28 Responders out of 34 and 6 non-Responders out of 23 (Sensitivity = 0.82, Specificity = 0.26, F1 Statistic= 0.71). The Positive (LR+) and Negative (LR-) Likelihood Ratios were respectively 1.11 and 0.68. The Diagnostic Odds Ratio (DOR) was equal to 2.Conclusions Preliminary clinical and technical results of a QNN Classifier tested on a relatively small knee osteoarthritis dataset show that quantum machine learning applied to data-driven clinical decisions is a promising technology. Our results need further research validation with larger, real-world unstructured datasets, and clinical validation with an AI Clinical Trial to test model efficacy, safety, clinical significance and relevance at a public health level.Competing Interest StatementThe authors declare that they have received support for the present manuscript in terms of provision of data and study materials. In the past 36 months, the authors have received grants from public research institutions and contracts from biomedical devices companies pertaining the field of digital health, digital medicine and osteoarthritis. The authors have received and are likely to receive in the future royalties, licenses, consulting fees, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events. Some parts of the Quantum Circuits and Artificial Intelligence algorithms are copyrighted and the authors are likely to patent some of the contents. The authors hold stock and stock options directly and indirectly in publicly traded and private biotech, medtech, digital health and healthcare companies. The authors declare no other competing interests.Funding StatementThis study received miscellanea funding from private institutions in the form of quantum computing hardware available for the research. No other funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was carried out in compliance with the rules of the Helsinki Declaration and International Ethical Regulations [Association et al., 2009], including all subsequent amendments, under the approval of the Research Ethics Committee of the George Emil Palade University of Medicine, Pharmacy, Science and Technology of Targu Mures, Romania (research approval number 1464/2021).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript